New Recruiting Trial: A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
WHY IT MATTERS
This trial offers a personalized monitoring approach for ALL patients in remission after CAR-T therapy, potentially reducing unnecessary treatments while catching early signs of relapse through genetic testing rather than standard methods alone.
Researchers are looking for children and young adults with a type of blood cancer called B-cell acute lymphoblastic leukemia (ALL) who have gone into remission after receiving CAR-T cell therapy. This study will use advanced genetic testing to monitor how well the patient's immune system recovers after treatment and help doctors decide on the best follow-up care plan.
NCT ID: NCT05621291 Title: A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu... Status: RECRUITING Phase: NA Sponsor: National Cancer Institute (NCI) Start date: 2026-05-06 URL: https://clinicaltrials.gov/study/NCT05621291 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If your child or young adult has B-cell ALL and recently achieved remission with CAR-T therapy, ask their oncologist about eligibility for this NCI-sponsored trial (NCT05621291), which begins recruiting in May 2026.